ribociclib
novartis
['maintain trial', 'bcsm', 'breast']
fifth oral #breastcancer abstract at #asco22: first promising data from #maintain trial showing potential role of cdk4/6 inhibition after prior cdk4/6i...the study also confirms the poor performance of endocrine therapy alone after cdk4/6i #bcsm 
Associate Professor at @UniGenova & Medical Oncologist at @SanMartino_Ge. Prior @myESMO fellow. #BreastCancer #Fertility. Big fan of @sampdoria & @giroditalia.